Quick Answer
Nurix Therapeutics, Inc. reported Net Income Loss of -$264.46 million for the year ending 2025.
- Nurix Therapeutics, Inc. showed a decrease of -36.6% in Net Income Loss from 2024 to 2025.
- This data is from Nurix Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on January 28, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$2.69 million | Q2 2019: -$3.07 million | Q3 2019: -$2.43 million | Q4 2019: -$13.52 million | Q1 2020: -$12.39 million | Q2 2020: $7.58 million | Q3 2020: -$18.52 million | Q4 2020: -$19.91 million | Q1 2021: -$24.28 million | Q2 2021: -$26.38 million | Q3 2021: -$28.84 million | Q1 2022: -$42.53 million | Q2 2022: -$45.40 million | Q3 2022: -$45.71 million | Q1 2023: -$40.73 million | Q2 2023: -$24.28 million | Q3 2023: -$36.98 million | Q1 2024: -$41.52 million | Q2 2024: -$44.55 million | Q3 2024: -$48.96 million | Q1 2025: -$56.35 million | Q2 2025: -$43.46 million | Q3 2025: -$86.42 million.
- Over the full 7 years of available data (2019 to 2025), Nurix Therapeutics, Inc.'s Net Income Loss has declined by 1,118.8%.
- Historical annual values: Fiscal year 2025: -$264.46 million | Fiscal year 2024: -$193.57 million | Fiscal year 2023: -$143.95 million | Fiscal year 2022: -$180.36 million | Fiscal year 2021: -$117.19 million | Fiscal year 2020: -$43.24 million | Fiscal year 2019: -$21.70 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: